| scholarly article | Q13442814 |
| P2093 | author name string | Robert A Hamilton | |
| Michael P Kane | |||
| Robert S Busch | |||
| AnneMarie Nardolillo | |||
| Jay Watsky | |||
| P2860 | cites work | Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 |
| Standards of medical care in diabetes--2014 | Q28304435 | ||
| Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes | Q34227891 | ||
| Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone | Q34543009 | ||
| Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis | Q36578983 | ||
| Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study | Q37022726 | ||
| Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial | Q37106527 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial | Q37302078 | ||
| Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications | Q37439364 | ||
| SGLT inhibitors in management of diabetes | Q38195440 | ||
| The potent synergistic effects of the combination of liraglutide and canagliflozin on glycemic control and weight loss | Q38834997 | ||
| Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial | Q43804231 | ||
| Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. | Q46046433 | ||
| Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. | Q51333570 | ||
| Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care | Q79866587 | ||
| Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR) | Q87791936 | ||
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 25-30 | |
| P577 | publication date | 2014-09-17 | |
| P1433 | published in | Clinical medicine insights. Endocrinology and diabetes | Q27724379 |
| P1476 | title | A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus | |
| P478 | volume | 7 |
| Q35830021 | Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis |
| Q40997631 | Health care provider experience with canagliflozin in real-world clinical practice: favorability, treatment patterns, and patient outcomes |
| Q33781497 | Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors. |
Search more.